公司资料
Lixte Biotechnology Holdings 股价、新闻与催化剂
- 股票代码:
- LIXT
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
7.21 USD (-6.00%)
收盘价
最后更新: 2026年7月2日
87.2M USD
市值
股价为何变动
The latest monitored company update is “NOMAD POWER SOLUTIONS FILES 2026 SECOND QUARTER FORM 10-Q, PROVIDES BUSINESS UPDATE.” Closing-price data for the corresponding market session is incomplete, so a relative move was not calculated.
公司概览
PP2A Inhibition in Cancer
LIXTE Biotechnology develops cancer therapies based on inhibition of protein phosphatase 2A. Its lead molecule is intended to sensitize tumors to chemotherapy and immunotherapy rather than function solely as a stand-alone cytotoxic drug.
LB-100
LB-100 is a first-in-class clinical PP2A inhibitor that has shown tolerability at biologically active doses. Proof-of-concept studies are evaluating combinations in ovarian clear-cell carcinoma, metastatic colorectal cancer and advanced soft-tissue sarcoma.
Proton-Therapy Technology
Through Liora Technologies Europe, LIXTE is also developing the LiGHT System, an electronically controlled proton-therapy platform. This med-tech program broadens the company beyond drug development into precision radiation treatment.
未来催化剂
- Lixte’s catalysts are oncology pipeline updates and any strategic move that clarifies the company’s next step. The market will care about whether there is still a viable clinical path.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。